🔗 Share this article

As the US undertakes sweeping revisions to its vaccination recommendations, an unexpected name has surfaced in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who initially gained attention by expressing skepticism about coronavirus vaccinations throughout the pandemic and has concentrated on possible fatalities after Covid vaccination in her recent position at the FDA.

Scheduled Overhauls to Pediatric Vaccine Program

Health officials had intended to announce sweeping revisions to the childhood vaccination calendar earlier this month, bringing the US with Denmark’s vaccine program, it is understood – a substantial departure that would place the US at odds with a large portion of the international standard with little proof for public health gain. The planned update has been delayed until the new year.

Instead of the director of the vaccine center, Høeg is scheduled to present at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the center this year.

A New Direction at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the drug and biologics centers as Dr. Høeg and Prasad consolidate power at the agency – and it suggests a increased emphasis upon reevaluating long-standing immunizations at the FDA.

Høeg has often pushed for discontinuing some pediatric vaccine recommendations in the US to become more similar to Denmark's approach, a society with comprehensive healthcare and a population approximately the size of the state of Wisconsin.

To date comments, she has persisted in emphasizing on vaccines – usually the domain of Dr. Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Doubts Over Background

Høeg has little discernible background in drug development, oversight or leadership, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“She appears not to have any of the qualifications” for running the pharmaceutical oversight division, said a neurologist and psychiatrist. “She’s never run a clinical trial. She is not versed in managing a major agency. She lacks background in drug approvals.”

Previous directors of the center would “grasp laws and regulations and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the type of experience that former directors who ran the center have had.”

This division has an enormous workload at the FDA, she emphasized.

“Many people just zeroes in on the innovative therapies, but the generic program approves a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and so forth, and every single one must be managed,” she noted. “The thing you overlook, that is the part that I always told people is going to cause problems.”

Additionally, a significant administrative component to the role, which supervises over 5,000 staff members. “It is a huge management job, if you perform it correctly,” Woodcock concluded.

Response and Controversial Programs

When asked about concerns about Dr. Høeg's qualifications and whether this selection represents more teamwork among FDA leaders on immunizations, a spokesperson said that the “concerns are based on flawed premises”.

“Her resume matches the functions of her job,” the representative said, citing the time Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Høeg inherits the commissioner’s new expedited review system, a controversial expedited drug-approval program that apparently troubled her preceding directors. “How are these drugs being chosen for this expedited pathway? Who makes the calls?” Dr. Howard asked. “There is a lot of lack of transparency happening at the regulatory body right now.”

In general, he stated, “the agency seems to be moving towards less stringent rules of most medications, aside from immunizations.”

Established History on Vaccines

Regarding immunizations, Høeg has a more documented, if troubling, history, some experts observe. She authored a study using non-validated volunteer-provided data to determine the rate of myocarditis after COVID-19 immunization. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccines are riskier than they are.

Part of her “wish list” for the new administration encompassed revising regulations for novel immunizations and ending “optional” immunizations, she said post-election on a podcast. At the FDA, Høeg has according to sources floated the idea of barring young men from obtaining COVID-19 vaccines.

“She is an thorough ideologue who commences with her preconceived notions and reverse-engineers to retrofit the data in a highly deceptive, fraudulent manner,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg became part of fellow dissenters, {like|